{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:55:39Z","timestamp":1760316939091,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.schres.2022.07.015","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T20:42:11Z","timestamp":1659732131000},"page":"58-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniform disorder: A post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) study"],"prefix":"10.1016","volume":"248","author":[{"given":"Larry","family":"Alphs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brianne","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Turkoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith H.","family":"Nuechterlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.schres.2022.07.015_bb0005","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4088\/JCP.14m09584","article-title":"Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study","volume":"76","author":"Alphs","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2022.07.015_bb0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.schres.2022.02.019","article-title":"The disease recovery evaluation and modification (DREaM) study: effectiveness of parliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder","volume":"243","author":"Alphs","year":"2022","journal-title":"Schizophr. Res."},{"year":"2020","series-title":"Practice Guideline for the Treatment of Patients With Schizophrenia","key":"10.1016\/j.schres.2022.07.015_bb0015"},{"key":"10.1016\/j.schres.2022.07.015_bb0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-244X-10-11","article-title":"Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia","volume":"10","author":"Ascher-Svanum","year":"2010","journal-title":"BMC Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2022.07.015_bb0025","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","article-title":"Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial","volume":"72","author":"Berwaerts","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.07.015_bb0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2013.05.016","article-title":"The evidence for illness progression after relapse in schizophrenia","volume":"148","author":"Emsley","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2022.07.015_bb0035","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-244X-13-50","article-title":"The nature of relapse in schizophrenia","volume":"13","author":"Emsley","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2022.07.015_bb0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophr. Res."},{"year":"2021","series-title":"INVEGA HAFYERA\u00ae (Paliperidone Palmitate) Extended-release Injectable Suspension, for Gluteal Intramuscular Use","author":"Janssen Pharmaceuticals, Inc","key":"10.1016\/j.schres.2022.07.015_bb0055"},{"year":"2021","series-title":"INVEGA TRINZA\u00ae (Paliperidone Palmitate) Extended-release Injectable Suspension, for Intramuscular Use","author":"Janssen Pharmaceuticals, Inc","key":"10.1016\/j.schres.2022.07.015_bb0050"},{"year":"2021","series-title":"INVEGA SUSTENNA\u00ae (Paliperidone Palmitate) Extended-release Injectable Suspension, for Intramuscular Use","author":"Janssen Pharmaceuticals, Inc","key":"10.1016\/j.schres.2022.07.015_bb0045"},{"issue":"Suppl. 14","key":"10.1016\/j.schres.2022.07.015_bb0060","first-page":"27","article-title":"Treatment strategies to prevent relapse and encourage remission","volume":"68","author":"Kane","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2022.07.015_bb0065","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","article-title":"Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial","volume":"77","author":"Kane","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2022.07.015_bb6000","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4088\/JCP.12r08167","article-title":"Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs","volume":"74","author":"Kirson","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2022.07.015_bb6005","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2022.07.015_bb0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/oxfordjournals.schbul.a007078","article-title":"The global costs of schizophrenia","volume":"30","author":"Knapp","year":"2004","journal-title":"Schizophr. Bull."},{"issue":"11","key":"10.1016\/j.schres.2022.07.015_bb0075","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1176\/appi.ps.201500455","article-title":"Hospital readmission rates among patients with schizophrenia treated with long-acting injectables or oral antipsychotics","volume":"67","author":"MacEwan","year":"2016","journal-title":"Psychiatric Serv."},{"issue":"12","key":"10.1016\/j.schres.2022.07.015_bb0080","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1080\/13696998.2018.1527608","article-title":"A comparison of treatment patterns, healthcare resource utilization, and costs among young adult medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US","volume":"21","author":"Manjelievskaia","year":"2018","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.schres.2022.07.015_bb0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1744-859X-12-32","article-title":"Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review","volume":"12","author":"Olivares","year":"2013","journal-title":"Ann. General Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2022.07.015_bb0095","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40273-017-0515-3","article-title":"The cost of relapse in schizophrenia","volume":"35","author":"Pennington","year":"2017","journal-title":"PharmacoEconomics"},{"issue":"1","key":"10.1016\/j.schres.2022.07.015_bb0100","first-page":"57","article-title":"Prevalence and psychosocial correlates of prior incarcerations in an urban, predominantly african-american sample of hospitalized patients with first-episode psychosis","volume":"39","author":"Ramsay","year":"2011","journal-title":"J. Am. Acad. Psychiatry Law"},{"key":"10.1016\/j.schres.2022.07.015_bb0105","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/NDT.S167394","article-title":"Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1","volume":"14","author":"Sajatovic","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"7","key":"10.1016\/j.schres.2022.07.015_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw018","article-title":"Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study","volume":"19","author":"Savitz","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.07.015_bb0115","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","article-title":"Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia","volume":"169","author":"Schreiner","year":"2015","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2022.07.015_bb0120","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/eip.13116","article-title":"Clinical effectiveness of early treatment with paliperidone palmitate in schizophrenia: A retrospective real-world study in South Korea","volume":"15","author":"Shin","year":"2021","journal-title":"Early Interv. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2022.07.015_bb0125","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophreniaA randomized clinical trial","volume":"72","author":"Subotnik","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2022.07.015_bb0130","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/0004867412470010","article-title":"Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review","volume":"47","author":"Taylor","year":"2013","journal-title":"Aust. N. Z. J. Psychiatry."},{"year":"2020","series-title":"2019\u20132020 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults","key":"10.1016\/j.schres.2022.07.015_bb0135"},{"key":"10.1016\/j.schres.2022.07.015_bb0140","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.2147\/NDT.S120298","article-title":"Self-stigma and schizophrenia: a cross-sectional study","volume":"12","author":"Vrbova","year":"2016","journal-title":"Neuropyschiatr. Dis. Treat."},{"issue":"6","key":"10.1016\/j.schres.2022.07.015_bb0145","doi-asserted-by":"crossref","first-page":"684","DOI":"10.4088\/JCP.13m08946","article-title":"The challenge of offering long-acting antipsychotic therapies: a prelimiary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia","volume":"76","author":"Weiden","year":"2015","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.schres.2022.07.015_bb0150","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-244X-8-72","article-title":"Costs of treating patients with schizophrenia who have illness-related crisis events","volume":"8","author":"Zhu","year":"2008","journal-title":"BMC Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996422002870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996422002870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:48:44Z","timestamp":1760298524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996422002870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":31,"alternative-id":["S0920996422002870"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2022.07.015","relation":{},"ISSN":["0920-9964"],"issn-type":[{"type":"print","value":"0920-9964"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniform disorder: A post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2022.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Janssen Scientific Affairs, LLC. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}